Company News: Novartis

Share this article:
Novartis and its vaccines/diagnostics division agreed to pay a $72.5-million settlement to resolve off-label marketing allegations involving cystic fibrosis drug TOBI. Novartis and predecessor Chiron Corp., according to a Justice Department statement, allegedly caused false claims to be submitted to the VA and other federal health programs between January 2001 and July 2006 by marketing the inhaled antibiotic for unapproved uses. To resolve their respective claims, the US is receiving $43.5 million and states $29 million. In connection with the qui tam suit, brought under the False Claims Act, three whistleblowers will share $7.825 million.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.